PR Newswire Clinical TrialsOriginal article
/C O R R E C T I O N -- Privo Technologies/
Phase 2PRV111Neutral
AI Analysis
Summary
Privo Technologies issued a correction to its October 5, 2026 news release regarding a clinical update from the ongoing Phase 2 trial of PRV111, a non-surgical therapy in development for early-stage oral cancer. The article does not provide specific trial data or outcomes.
Clinical Trial Data
Phase
2
Importance:2/10
Sentiment:
0.00
Phase 2Oral CancerNon-surgical therapyCorrection
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 7, 2026 4:31 PM